Recombinant preparations of GM-CSF have been widely used to support myeloid reconstitution after hematopoietic stem cell transplantation, to treat neutropenia during chemotherapy, or to ameliorate radiation-induced myelosuppression (51, 52). The gene discussed is CSF2; the disease is Decreased total neutrophil count.